- AMX-883-mediated BRD9 degradation disrupts hematopoietic transcriptional programs, promotes myeloid differentiation, and depletes leukemic stem cells in acute myeloid leukemia (AML)
- Additional abstract on AMX-883 BRAMLIE trial assessing safety, pharmacokinetics, and preliminary efficiency to publish in Blood
Amphista Therapeutics Limited ('Amphista' or 'the Company'), a clinical-stage biopharmaceutical company focused on the discovery and development of non-cereblon VHL targeted protein degradation (TPD) medicines, today announced new data on its lead therapeutic candidate, AMX-883, has been accepted for oral presentation at American Society of Hematology (ASH) Annual Meeting in New Orleans, December 12-15, 2026. The full abstract is available online: www.hematology.org/Meetings/Annual-Meeting/Abstracts
The data, to be presented by Dr Louise Modis, CEO, suggest BRD9 plays a critical role in acute myeloid leukemia (AML), maintaining activity of a number of hematopoietic transcription factors. Degradation of BRD9 using AMX-883 restricts these transcription factor programs, releasing the differentiation block and reducing the frequency of leukemic stem cells.
Presentation details:
- Title: AMX-883-mediated BRD9 degradation disrupts hematopoietic transcriptional programs, promotes myeloid differentiation, and depletes leukemic stem cells in acute myeloid leukemia
- Session: 604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Cell-Intrinsic and Niche-Mediated Mechanisms of Drug Resistance in AML. December 14, 2026, 10:30 AM 12:00 PM
- Room: MCCNO Great Hall BC
- Presentation time: December 14, 2026, 11:45 AM 12:00 PM
- Publication number: 762
- Submission ID: abs26-9908
The second abstract, due to be published in the ASH Blood Supplement, highlights Amphista's ongoing AMX-883 BRAMLIE trial (1), an open label, multi-part, dose escalation and optimization study:
- Abstract number: abs26-2088
- Title: A Phase 1, open-label, multi-centre study to assess the safety, pharmacokinetics, and preliminary efficacy of AMX-883 monotherapy in participants with acute myeloid leukemia and high-risk myelodysplastic syndrome and in combination in participants with AML
- Category: 600s Hematologic Malignancy
- Review category: 616. Acute Myeloid Leukemias: lnvestigational Drug and Cellular Therapies
- Authors: Eytan Stein, Emma Searle, Amir Fathi, Jayastu Senapati, Justin Watts, Victoria Campbell, Jenny O'Nions, Alexander Spira, David Taussig, Paul Player, Giulia Petrone, Anthony Selwyn Stein, Lisa Butler, Patrick Kelly
- https://amphista.com/amphista-therapeutics-announces-first-patient-dosed-in-amx-883-phase-1-clinical-trial-for-acute-myeloid-leukemia/
View source version on businesswire.com: https://www.businesswire.com/news/home/20261104368537/en/
Contacts:
Media contact:
Lorna Cuddon
Zyme Communications
Tel: +44(0)7811 996 942
Email: lorna.cuddon@zymecommunications.com
